Cobra Biologics and Novolytics Develop Bacteriophages Against Infection
Wednesday, June 12, 2013
Companies have achieved a breakthrough in the development of two Staphylococcus aureus-based phage products for Phase I clinical trials.

Big Multiple Sclerosis Breakthrough
Tuesday, June 11, 2013
Phase 1 trial safely resets patients’ immune systems, reduces attack on myelin protein.

BioLineRx Enters Into Collaboration with CTTQ
Tuesday, June 11, 2013
CTTQ receives development and commercialization rights in China and Hong Kong.

Almac Discovery Announces Licensing of ALM201 to Shin Poong
Tuesday, June 11, 2013
Licensing of novel anti-angiogenic peptide for development and marketing in South Korea.

Galapagos to Raise Capital Via a Private Placement of New Shares
Tuesday, June 11, 2013
Proceeds to be used for future portfolio opportunities.

SCHOTT to Strengthen Pharmaceutical Site in Hungary
Monday, June 10, 2013
New maintenance facility will be opened in the Lukácsháza region.

Ferrer Successfully Completes a Phase III Clinical Trial in Adult and Paediatric Patients with Impetigo
Monday, June 10, 2013
Ozenoxacin, a novel bactericidal non-fluorinated quinolone, in development as a topical treatment for impetigo and other infectious dermatological conditions, is now available for licensing and commercialization from Ferrer.

Santhera Secures Exclusive Rights from NIH
Monday, June 10, 2013
Santhera has obtained the exclusive rights to the use patent for idebenone in ppMS granted in the USA.

<<	1 2 3 4 5 6 7	>>
Showing Results 11 - 20 of 2318